Patents by Inventor Christoph Kalis

Christoph Kalis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K FOR THE TREATMENT OF PRIMARY SJOGREN'S SYNDROME
    Publication number: 20190038628
    Abstract: The invention relates to the use of 1-{(S)-3-[6-(6-methoxy-5-trifluoromethyl-pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-one or pharmaceutically acceptable salts thereof for the treatment of primary Sjögren's Syndrome.
    Type: Application
    Filed: February 10, 2017
    Publication date: February 7, 2019
    Inventors: Bruno BIETH, Christoph BURKHART, Andreas CHRIST, Stefan DE BUCK, Christoph KALIS, Sam LINDGREN
  • Use of inhibitors of the activity or function of PI3K
    Patent number: 9949979
    Abstract: The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: April 24, 2018
    Assignee: Novartis AG
    Inventors: Nigel Graham Cooke, Paulo Antonio Fernandes Gomes Dos Santos, Pascal Furet, Christina Hebach, Klemens Hoegenauer, Gregory Hollingworth, Christoph Kalis, Ian Lewis, Alexander Baxter Smith, Nicolas Soldermann, Frederic Stauffer, Ross Strang, Frank Stowasser, Nicola Tuffilli, Anette Von Matt, Romain Wolf, Frederic Zecri
  • Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives
    Publication number: 20160106753
    Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: December 21, 2015
    Publication date: April 21, 2016
    Applicant: Novartis AG
    Inventors: Giorgio CARAVATTI, Sylvie CHAMOIN, Pascal FURET, Klemens HOGENAUER, Konstanze HURTH, Christoph KALIS, Karen KAMMERTOENS, Ian LEWIS, Henrik MOEBITZ, Alexander Baxter SMITH, Nicolas SOLDERMANN, Romain WOLF, Frederic ZECRI
  • Use of Inhibitors of the Activity or Function of PI3K
    Publication number: 20150342951
    Abstract: The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.
    Type: Application
    Filed: December 14, 2012
    Publication date: December 3, 2015
    Applicant: NOVARTIS AG
    Inventors: Nigel Graham COOKE, Paulo Antonio FERNANDES GOMES DOS SANTOS, Pascal FURET, Christina HEBACH, Klemens HOGENAUER, Gregory HOLLINGWORTH, Christoph KALIS, Ian LEWIS, Alexander Baxter SMITH, Nicolas SOLDERMANN, Frederic STAUFFER, Ross STRANG, Frank STOWASSER, Nicola TUFFILLI, Anette VON MATT, Romain WOLF, Frederic ZECRI
  • Quinoline Derivatives
    Publication number: 20150148377
    Abstract: The invention relates to quinoline compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, W, U, Q, R1, R5 R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.
    Type: Application
    Filed: December 20, 2012
    Publication date: May 28, 2015
    Applicant: NOVARTIS AG
    Inventors: Klemens Hogenauer, Konstanze Hurth, Christoph Kalis, Henrik Moebitz, Nicolas Soldermann, Frederic Zecri